Lupin Signs Exclusive Deal With Visus Therapeutics For Yuvezi For Up To €75 Million

Market snapshot: Lupin Limited's wholly owned subsidiary, VISUfarma B.V., has entered into an exclusive licensing deal with Visus Therapeutics to commercialize its FDA-approved presbyopia eye drop, YUVEZZI™, in Europe. The transaction is valued at up to €75 million, which includes a €20 million strategic equity investment and up to €55 million in commercial and regulatory milestones.

Data Snapshot

• Exclusive licensing agreement for YUVEZZI™ covers the European Union, the United Kingdom, Switzerland, Norway, and Iceland.
• Total consideration consists of a €20 million strategic equity investment via a Simple Agreement for Future Equity (SAFE) instrument and up to €55 million in milestone payments.

What's Changed

• This exclusive licensing deal follows Lupin's recent acquisition and consolidation of Netherlands-based VISUfarma B.V. in April 2026, marking a significant ramp-up in its European specialty ophthalmic franchise.

Key Takeaways

• VISUfarma B.V., Lupin's wholly owned European subsidiary, gains exclusive rights to commercialize YUVEZZI™ (carbachol and brimonidine tartrate) across the EU, UK, Switzerland, Norway, and Iceland.
• The deal is structured as a €20 million strategic investment in Visus via a SAFE instrument, plus up to €55 million contingent on regulatory and commercial milestones.
• YUVEZZI™ is a highly differentiated asset, being the first and only once-daily, dual-agent ophthalmic solution approved for adult presbyopia (gradual loss of near vision).
• This move solidifies Lupin’s Specialty Care strategy and leverages VISUfarma’s established commercial footprint in European vision care markets.

SAHI Perspective

This partnership is a smart capital-allocation play by Lupin. By utilizing its recently consolidated VISUfarma subsidiary, Lupin is effectively plugging a highly differentiated, FDA-approved asset (YUVEZZI™) into an established European distribution network. The structured payment system—anchored by a €20 million strategic SAFE equity position and back-ended with up to €55 million in regulatory/commercial milestone payments—mitigates upfront commercialization risks while ensuring skin in the game.

Market Implications

The deal enhances Lupin’s specialty pharmaceutical positioning, reducing its reliance on highly competitive generic markets in the US. Commercial success of YUVEZZI™ in Europe will provide high-margin royalty streams and diversify geographic revenue streams.

Trading Signals

Market Bias: Bullish

The deal represents an excellent high-margin expansion of Lupin's European specialty eye-care franchise, leveraging the recently consolidated VISUfarma. Additionally, Lupin reported solid Q1 FY27 results on August 6, 2026, with revenue rising 32.04% YoY to ₹8,277 crore and PAT increasing 16.01% YoY to ₹1,417 crore.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Successful regulatory filings and launches of YUVEZZI™ in European markets
• Progress of the clinical pipeline of Visus Therapeutics
• Quarterly growth metrics of Lupin's European specialty business

Time Horizon: Medium-term (3-12 months)

Industry Context

The ophthalmic therapeutics market is seeing substantial growth due to aging populations. Presbyopia typically affects adults starting around age 45. FDA-approved once-daily therapies like YUVEZZI™ represent a major paradigm shift away from reading glasses towards topical medical treatments.

Key Risks to Watch

• Regulatory approval timelines and adoption hurdles for YUVEZZI™ in European jurisdictions.
• Market penetration rates in highly price-sensitive European healthcare reimbursement systems.
• Valuation fluctuations of the €20 million strategic investment made via the SAFE instrument depending on Visus Therapeutics' future funding rounds or public listing.

Recent Developments

During this window, Lupin made several key announcements: • On August 06, 2026, the company posted record Q1 FY27 revenue of ₹8,277 crore (up 32.04% YoY) and PAT of ₹1,417 crore (up 16.01% YoY). • On June 26, 2026, Lupin received tentative US FDA approval for Enzalutamide Tablets. • On June 04, 2026, the company secured US FDA approval for Ranluspec, its interchangeable biosimilar referencing Lucentis.

Closing Insight

Lupin's strategic focus on building a robust specialty eye care business is paying off. By combining organic biosimilar achievements (such as Ranluspec™) with targeted licensing agreements like YUVEZZI™ under VISUfarma, Lupin is successfully building a global, high-margin, and highly defensible specialty care franchise.

High Performance Trading with SAHI.